Related by context. All words. (Click for frequent words.) 66 sunitinib malate 66 Phase Ib II 65 Phase #b/#a clinical 65 SUTENT ® 65 refractory chronic lymphocytic 65 Bayer HealthCare Onyx Pharmaceuticals 64 BrachySil TM 64 neratinib 64 Pertuzumab 64 Deforolimus 63 ThermoDox ® clinical 63 BRIM3 63 OvaRex R 63 Gastrointestinal Stromal Tumors 63 Dacogen injection 63 Dose Escalation 63 rALLy clinical trial 63 Cloretazine ® 63 sorafenib Nexavar 63 Romiplostim 63 Hsp# Inhibitor 63 Pivotal Trial 63 Phase Ib Clinical Trial 63 alvespimycin 62 BRIM2 62 LUMINATE 62 Xelox 62 YONDELIS 62 Temsirolimus 62 Prospective Randomized 62 Xanafide 62 Prolongs Survival 62 trastuzumab DM1 T DM1 62 Allovectin 7 ® 62 omacetaxine mepesuccinate 62 Ixempra 62 HDAC Inhibitor 62 Tanespimycin 62 Triapine 62 Zenvia Phase III 62 ZACTIMA 62 evaluating REVLIMID 62 Phase #/#a trial 62 Combination REOLYSIN R 62 phase IIb clinical 62 MYCAMINE 61 CHAMPION PCI 61 ANTEGREN 61 Cardiotoxicity 61 Pivotal Phase 61 BR.# 61 HCV Protease Inhibitor 61 Antisoma AS# 61 assessing T DM1 61 Phase III Clinical Trial 61 Brentuximab Vedotin SGN 61 TroVax ® 61 Phase IIIb clinical 61 Glufosfamide 61 Tesmilifene 61 Xcellerated T Cells 61 enzastaurin 61 PANVAC VF 61 Heart Transplant Recipients 61 See CLINICAL PHARMACOLOGY 61 PRESEPT 61 Romidepsin 61 Daclizumab 61 Phase IIb III 61 INCB# [001] 61 AVAX 61 Preclinical Models 61 Myelodysplastic Syndromes 61 Ceflatonin 61 including eniluracil ADH 61 ixabepilone 61 p# biomarker 61 Phase Ib IIa 61 Phase III TRIST 61 seliciclib CYC# 61 Phase IIIb 61 Ceflatonin R 61 Phase Ib study 61 Hormone Refractory Prostate Cancer 61 Immunotherapeutic 61 First Patient Enrolled 61 MEK Inhibitor 61 Severe Sepsis 61 preclinical efficacy 61 Hedgehog Pathway Inhibitor 61 CYT# potent vascular disrupting 61 BLP# Liposome Vaccine 61 Carfilzomib 61 Phase Ib clinical 60 forodesine 60 Metastatic Renal Cell Carcinoma 60 Fabry Disease 60 Phase 1b clinical trials 60 Phase #/#a 60 Hepatocellular Carcinoma HCC 60 FOLOTYN ® 60 Acute Ischemic Stroke 60 Antitumor Activity 60 TTF Therapy 60 oral ridaforolimus 60 MOZOBIL 60 Oral Fingolimod 60 Interferon beta 1a 60 gefitinib Iressa 60 evaluating tivozanib 60 Velcade bortezomib 60 LBH# 60 Acute Decompensated Heart Failure 60 Lenalidomide 60 R lenalidomide 60 Blinatumomab 60 TheraSphere R 60 IL# PE#QQR 60 relapsed refractory multiple myeloma 60 Preclinical Efficacy 60 pain palliation 60 Pazopanib 60 Phase 2b Clinical Trial 60 STRIDE PD 60 Patient Outcomes 60 L BLP# 60 Golimumab 60 ThermoDox R 60 Vion Pharmaceuticals 60 Allovectin 7 60 Archexin 60 Phase III multicenter 60 Phase IIa trials 60 Amrubicin 60 Anticancer Drug 60 Azedra 60 GATTEX TM 60 lumiliximab 60 Vidaza azacitidine 60 HuMax EGFr 60 Pirfenidone 60 REVEAL Registry 60 refractory metastatic 60 Tumor Response 60 tramiprosate Alzhemed TM 60 Adult Stem Cell Therapy 60 pharmacogenomic translational research 60 Renal Cancer 60 LymphoStat B TM 60 CLARITY study 59 Unresectable 59 PF # [002] 59 Investigator Initiated 59 axitinib 59 CAMPATH 59 Cloretazine 59 AML acute myeloid 59 BEXXAR Therapeutic Regimen 59 personalized immunotherapy 59 Adaptive Radiation Therapy 59 Prostate AdenoCarcinoma Treatment 59 phase IIb trial 59 sunitinib Sutent 59 recurrent NSCLC 59 sapacitabine CYC# 59 kidney urologic 59 Truvada tablets 59 registrational trial 59 Oncotype 59 REVIVE Diabetes 59 elacytarabine 59 EXPLORE Xa 59 SUCCEED trial 59 Pivotal Study 59 teriflunomide 59 Clinical Trial Results 59 cytoreductive nephrectomy 59 PROSTASCINT R 59 APTIVUS 59 AVASTIN 59 Hepatocellular Carcinoma 59 ALN HPN 59 Topline Results 59 Revlimid lenalidomide 59 chronic idiopathic thrombocytopenic purpura 59 NABTT 59 phase IIa clinical 59 Follicular Lymphoma 59 Newly Diagnosed Multiple Myeloma 59 GW# [003] 59 haematologic malignancies 59 myelofibrosis polycythemia vera 59 tanespimycin 59 chemotherapeutic regimen 59 Novel Oral 59 Study Evaluating 59 Genasense ® 59 blinded randomized placebo controlled 59 Aplidin 59 Specifid 59 randomized controlled Phase 59 Tyrosine Kinase Inhibitors 59 Renal Cell Carcinoma RCC 59 ENESTnd 59 farletuzumab 59 Pixuvri 59 ganetespib 59 refractory CLL 59 histone deacetylase HDAC inhibitor 59 Safinamide 59 Therapy Evaluation 59 HGS# 59 Pivotal Clinical Trial 59 Randomized Study 59 Acute Heart Failure 59 romidepsin 59 intravesical infusion therapy 59 Ocrelizumab 59 HCV SPRINT 59 pediatric acute lymphoblastic 58 Hematological Malignancies 58 brivaracetam 58 NSABP B 58 CIMZIA TM certolizumab pegol 58 Chemophase 58 CEQ# 58 OncoVEX GM CSF 58 Vascugel ® 58 Alemtuzumab 58 Cimzia TM 58 lexidronam injection 58 number NCT# ClinicalTrials.gov 58 Maven Semantic 58 Left Ventricular Dysfunction 58 tumor vascular disrupting 58 relapsed MM 58 CUSTOM III 58 Vandetanib 58 Celgene Revlimid 58 Omacetaxine 58 Exelixis XL# 58 refractory AML 58 Entereg TM 58 Gleevec imatinib mesylate 58 registrational Phase 58 pharmacokinetic PK study 58 Renal Cell Carcinoma 58 Pulmonary Arterial Hypertension 58 Metastatic Melanoma 58 European Sepsis Trial 58 Panitumumab 58 investigational immunotherapy 58 depsipeptide 58 Pemetrexed 58 phase Ib 58 deforolimus 58 ICON7 58 lintuzumab 58 EGFR HER2 58 Phase 2b Trial 58 DASISION 58 BRAF inhibitor 58 ProMune 58 MEK inhibitors 58 Multicenter Phase 58 APEX PD 58 Li Fraumeni Syndrome 58 LUX Lung 58 ASCO GI 58 EGS# 58 Synta Announces 58 HuMax CD4 58 HER2 positive metastatic breast 58 TASKi2 58 Antiviral Activity 58 IMPACT DCM 58 metastatic neuroendocrine tumors 58 Certican 58 Phase IIIb study 58 phase IIa 58 Bone Marrow Transplants 58 Septin9 58 Chronic Lymphocytic Leukemia 58 riociguat 58 Mycophenolate mofetil 58 ToGA 58 Intravenous CP 58 Laryngeal Cancer 58 recurrent glioma 58 Randomized Phase 58 neoadjuvant treatment 58 sorafenib tablets 58 Analytical Tool 58 Diamyd Medical Diamyd 58 Degarelix 58 EOquin TM 58 pertuzumab 58 anti angiogenic agents 58 Zenvia ™ 58 Boceprevir 58 Thorough QT 58 PSMA ADC 58 Gastric Cancer 58 placebo controlled Phase III 58 II Clinical Trial 58 Crit Rev 58 tolerability pharmacokinetics 58 Randomized Double blind 58 Plicera 58 ReN# 58 hematological malignancy 57 randomized Phase IIb 57 OvaRex 57 Trandolapril 57 GVAX Pancreas Vaccine 57 OLYMPIA registry 57 Nasdaq ONXX today 57 Randomized Phase III 57 recurrent glioblastoma multiforme 57 multicenter Phase 57 Aplidin R 57 IMPACT IMmunotherapy 57 Randomized Clinical Trials 57 Denufosol 57 HoFH 57 NSABP C 57 APPRAISE 57 darinaparsin ZIO 57 metastatic gastric 57 Ibritumomab Tiuxetan 57 Pooled Analysis 57 CIMZIA ™ 57 LHRH antagonists 57 CCX# 57 Quinamed 57 ANCHOR trial 57 alemtuzumab Campath 57 Advaxis Phase 57 Neuvenge 57 Lymphocytic 57 RX ACCULINK 57 Mipomersen 57 Gemzar ® 57 QUADRAMET R 57 Randomized Double Blind 57 celgosivir 57 Cloretazine R 57 TRISENOX 57 Ambrisentan 57 Natalizumab 57 Epratuzumab 57 Nexavar sorafenib 57 phase IIb study 57 Omapro 57 metastatic malignant 57 SNT MC# 57 Clostridium difficile Infection 57 vinca alkaloid 57 HQK 57 CRLX# 57 AVN# Phase 57 ERYtech 57 cardio renal 57 abiraterone acetate 57 Computed Tomographic 57 Randomized Phase II 57 Ganite ® 57 Biomarker Study 57 pemetrexed Alimta 57 randomized Phase 2b 57 ExCell study 57 lorcaserin Phase 57 adult chronic ITP 57 NEUVENGE 57 Aflibercept 57 PROSTVAC TM 57 CINtec R 57 PEG SN# 57 ongoing Phase 1b 57 BCIRG 57 haematological cancers 57 Diasome 57 Enzyme Replacement Therapy 57 Proxinium TM 57 VALOR trial 57 GOUT 57 refractory colorectal cancer 57 Accelerated Partial Breast Irradiation 57 Carotid Endarterectomy 57 cetuximab Erbitux 57 immatics 57 myelodysplastic syndromes MDS 57 EXPAREL ™ 57 By JENNIFER LEARN 57 relapsing multiple sclerosis 57 GERD migraine headaches 57 Decitabine 57 Dacogen TM 57 cediranib 57 Coronary Artery Bypass Graft 57 Phase III HEAT 57 Radioimmunotherapy 57 Adjuvant Therapy 57 Dasatinib 57 ICAEL 57 Neoadjuvant Chemotherapy 57 Voraxaze ™ 57 KRN# 57 Amgen Vectibix 57 MelaFind R 57 elotuzumab 57 Minimally Invasive Procedure 57 aromatase inhibitor AI 57 Refractory Angina 57 Phase Ib 57 Phase 2a Trial 57 clevidipine 57 budesonide foam 57 decitabine 57 Phase IIB 57 lomitapide 57 Allogeneic 57 Eraxis 57 Recurrent Breast Cancer 57 Taxotere ® 56 Sym# 56 Carotid Stenting 56 Prostate Cancer Patients 56 EchoCRT 56 BEXXAR 56 metastatic colorectal 56 registrational 56 Epidermal Growth Factor Receptor 56 Stimuvax R 56 mitogen activated ERK kinase 56 CIMZIA TM 56 PROSTVAC ® 56 SUTENT 56 via intradermal injections 56 metastatic renal cell 56 Demonstrates Sustained 56 RELOVAIR ™ 56 Hodgkin lymphoma HL 56 entinostat 56 Virulizin ® 56 Traficet EN 56 Efficacy Trial 56 Combidex 56 vidofludimus 56 XLTEK 56 XL# SAR# 56 hormone refractory metastatic prostate 56 Orazol 56 gemcitabine Gemzar ® 56 prospective multicentre 56 eltrombopag 56 metastatic CRC 56 CALGB 56 acute PAO 56 Zybrestat 56 Hormone Receptor Positive 56 CR# vcMMAE 56 ALN TTR 56 SIR Spheres 56 ENDEAVOR IV 56 CLL8 56 Bone Metastases 56 Rheumatoid Arthritis Patients 56 Malignant Glioma 56 Edge STudy 56 Phase #b/#a 56 cancer mCRC 56 pancreatic islet cell 56 ISTODAX ® 56 IMC #B 56 Oral Mucositis 56 familial amyloidotic polyneuropathy FAP 56 Cloretazine R VNP#M 56 Double Blind Placebo 56 biologic DMARD 56 phase IIb 56 PERSEUS 56 Rilonacept 56 IRX 2 56 AEG# 56 MGd 56 RUGs IV 56 CT Angiography 56 Patient Accrual 56 bevacizumab Avastin 56 PNH patients 56 Outpatient Setting 56 Late Breaker 56 demethylating agent 56 Uterine Fibroid Embolization 56 prospective multicenter study 56 diseases fat malabsorption 56 Targeted Therapies 56 standard chemotherapy regimen 56 HGS ETR1 56 IRESSA 56 AeroLEF TM 56 multicenter Phase II 56 Sunesis Pharma 56 CALGB # [002] 56 TRO# 56 Fibrillex TM 56 peginesatide 56 R# #mg BID 56 Contrast Echocardiography 56 mRCC 56 rALLy trial 56 bortezomib Velcade 56 YONDELIS R 56 MEND CABG 56 Removab 56 ARCOXIA 56 Gleevec resistant 56 TheraSphere 56 COSIRA trial 56 candidate CRLX# 56 Sipuleucel T 56 Gamunex C 56 GenPath 56 Lomitapide 56 TRANSDUR ™ 56 Hyphanox 56 AIR2 Trial 56 ASPIRE HIGHER 56 Adjuvant Chemotherapy 56 MDS AML 56 Bortezomib 56 Chronic Heart Failure 56 Gentium Announces 56 Zarnestra 56 CAMMS# 56 hematopoietic malignancies 56 dirucotide MBP# 56 Arranon 56 Aortic Stenosis 56 Clinical Trials Update 56 gastro intestinal inflammation 56 Chronic Myeloid Leukemia 56 biliary tract cancer 56 Lung Cancer Trial 56 concurrent chemoradiation 56 tyrosine kinase inhibitor TKI 56 IV Busulfex 56 Clinical Trial Data 56 Phase III ThermoDox 56 EndoTAG TM -1 56 Recurrent Chest Wall 56 Eluting Stent 56 Combination Treatment 56 Clinical Outcome 56 multiple myeloma MM 56 ADVANCE PD 56 metastatic hormone refractory 55 metastatic castration resistant 55 PEGylated interferon beta 1a 55 non metastatic osteosarcoma 55 PROLARIS 55 DF HCC 55 Alocrest 55 chemoprevention trials 55 chronic thromboembolic pulmonary 55 HuLuc# 55 NCIC CTG 55 Randomized Evaluation 55 proteasome inhibitor 55 PNT# 55 Fungal Infections 55 Advanced Renal Cell 55 ADVEXIN 55 NO# [002] 55 PXD# 55 Peptidomics 55 targeting miR 55 specific CCR9 antagonist 55 Antiviral Therapy 55 vascular disrupting agent 55 intravenous methylnaltrexone 55 Li Fraumeni 55 Castration Resistant Prostate Cancer 55 Phase III Clinical Trials 55 Angiolix 55 Heart Failure Patients 55 randomized Phase III 55 multicenter prospective 55 AS# amonafide L malate 55 XL# XL# XL# 55 samarium Sm 55 Ovarian Cancers 55 REG2 55 TMC# C# 55 OPT CHF 55 CAPACITY trials 55 Onrigin 55 dose escalation clinical 55 Stent Thrombosis 55 ABSORB clinical 55 Doxil ® 55 pharmacokinetic PK 55 standard chemotherapy regimens 55 Drug Prevents 55 Prospective Multicenter 55 RGB # 55 TCGA Pilot Project 55 Phase III psoriasis 55 MERLIN TIMI 55 multicenter phase 55 Perifosine 55 Watchful Waiting 55 ALN VSP Phase 55 Phase 1b trial 55 Onco TCS 55 efalizumab 55 Randomized Controlled Trials 55 R roscovitine 55 Nuvion 55 follicular lymphoma FL 55 Hematological Cancers 55 Watson LIMS 55 RE MODEL 55 TRANSFORMS 55 Syllego system 55 pharmacogenetic testing 55 PRTX 55 ER CHOP 55 LibiGel Phase III 55 ELACYT 55 Pfizer Camptosar 55 Hepatitis C Infection 55 Myelodysplastic syndrome 55 HCV NS5B polymerase 55 randomized multicenter Phase III 55 MET amplification 55 hypomethylating agents 55 Erlotinib 55 HER2 overexpression 55 ponatinib 55 #nd EORTC NCI 55 Myelofibrosis 55 Talotrexin 55 Potent Antiviral Activity 55 Talabostat 55 sipuleucel T 55 Inflammatory Diseases 55 Immunogenicity 55 vandetanib 55 transthyretin TTR mediated amyloidosis 55 TAXOL 55 NKI AVL 55 Dr. McHutchison 55 Votrient 55 targeting CD# 55 Double Blind Randomized 55 Sorafenib 55 Enzastaurin 55 Myelodysplastic syndromes MDS 55 Autologous Stem Cell Transplantation 55 myelodysplastic syndromes 55 ISEL 55 AVERROES 55 ProSavin 55 PROSTVAC VF 55 Chronic Hepatitis C 55 HORIZONS AMI trial 55 Vernakalant 55 atypical Hemolytic Uremic Syndrome 55 Virulizin R 55 RECORD1 55 NovoTTF 55 ZYBRESTAT 55 PROCRIT R 55 recurrent GBM 55 #rd Annual CTRC 55 commercialize deforolimus 55 Multiple Myeloma Patients 54 Hematological 54 AA Amyloidosis 54 Caris MPI 54 LungSign TM 54 ENDEAVOR III 54 Decompensated Heart Failure 54 PIX# [002] 54 MT#/MEDI-# 54 Eculizumab 54 Supportive Care 54 Preclinical Study 54 AVADO 54 Neuroendocrine Tumors 54 Advanced Heart Failure 54 TAXUS ATLAS 54 Nonclinical 54 Breast Cancer Recurrence 54 Delcath Phase III 54 SABCS 54 metastatic renal cell carcinoma 54 anastrozole Arimidex 54 Antiplatelet Therapy 54 R#/MEM # 54 CERVARIX 54 Sequencing Systems 54 GRN# 54 Cancer Immunotherapy 54 Phase IIIB IV 54 transplantation HCT 54 Metastatic Prostate Cancer 54 stage IIIB 54 PERSEUS clinical program 54 OvaRex MAb 54 Diabetic Nephropathy 54 Valsartan 54 prelicensure 54 oral FTY# 54 Acute myeloid leukemia 54 Cardiometabolic 54 Panzem 54 www.ilgenetics.com 54 Relapsing Remitting Multiple Sclerosis 54 NATRECOR R 54 FDG PET imaging 54 TransVax ™ 54 Adjuvant Breast Cancer 54 Squamous 54 Alexion Pharma 54 systemic Phase 1b 54 CTRC AACR 54 multicenter randomized Phase 54 allogeneic bone marrow 54 Chronic Myelogenous Leukemia 54 OPTIMIZE 54 Folotyn 54 LSE ASM 54 concurrent ITP 54 allogeneic stem cell 54 ATIR TM 54 ONTARGET 54 Curon Medical 54 multicenter clinical 54 Myelodysplastic Syndrome MDS 54 direct thrombin inhibitors 54 NYSE MDZ TSX 54 Anthracycline 54 Oncogenex 54 dacetuzumab 54 opioid naive 54 Patient Registry 54 Long Lesion 54 oral deforolimus 54 Ridaforolimus 54 Onrigin TM 54 lymphoma CTCL 54 Abiraterone Acetate 54 ST Segment Elevation 54 RE LY 54 Tarvacin TM 54 ThermoDox ® 54 INS# [002] 54 Islet Transplantation 54 AIM HIGH 54 Idiopathic Pulmonary Fibrosis 54 PRoFESS 54 hematopoietic cell 54 Randomized Clinical Trial 54 BIBW 54 entitled Synergistic 54 nonsmall cell lung cancer 54 LymphoStat B 54 ILLUMINATE 54 OHR/AVR# 54 Node Negative 54 cat dander allergy 54 Cerner Millennium ® 54 stem cell engraftment 54 OPAXIO 54 laparoscopic radical nephrectomy 54 Avastin bevacizumab 54 romiplostim 54 ExTRACT TIMI 54 IMGN# 54 INTERCEPT platelets 54 KRAS status 54 Dacogen decitabine 54 Myelodysplastic Syndrome 54 APEX AMI trial 54 Study Shows Promise 54 ORACLE MS 54 Leukemias 54 initiate multicenter 54 Dendreon Provenge 54 Phase 2a clinical 54 vincristine doxorubicin 54 CD# monoclonal antibody 54 EVEREST II 54 Acute Coronary Syndromes 54 NCCTG 54 Max Neeman 54 CombAT 54 PRIALT 54 Systemic Lupus Erythematosus SLE 54 Endometrial Cancer 54 satraplatin Phase 54 5q deletion 54 ONX 54 aflibercept 54 CoFactor 54 placebo controlled Phase 54 Teplizumab 53 Metabasis Therapeutics 53 carotid artery stenting 53 obatoclax 53 Valera Pharmaceuticals 53 Onconase 53 clinical pharmacology studies 53 lucinactant 53 Novartis Gleevec 53 Phase III Trials 53 Randomized Trials 53 Rasilez Tekturna 53 Epidemiological Studies Unit 53 pazopanib 53 Stage IIIb 53 Ranolazine 53 Phase 2b RESTORE CLI 53 Inflammatory Markers 53 cytogenetic abnormalities 53 Treating Chronic 53 Surgical Treatment 53 basal bolus regimen 53 leukemia AML 53 huC# DM4 53 tasocitinib 53 EHR Adoption 53 paroxysmal nocturnal hemoglobinuria 53 RE LY ® 53 trastuzumab Herceptin 53 smoldering myeloma 53 Glioma 53 Olaparib 53 Halozyme Ultrafast Insulin 53 AASLD Meeting 53 RECIST Response Evaluation Criteria 53 CA4P 53 vismodegib 53 chemotherapy hormonal therapy 53 mifamurtide L MTP PE 53 Screening Trial 53 Poster Discussion 53 Arimidex anastrozole 53 Traumatic Spinal Cord Injury 53 simplex virus 53 Nonalcoholic Steatohepatitis 53 ProLindac 53 NCT# ClinicalTrials.gov 53 HORIZONS AMI 53 ACUITY trial 53 trastuzumab DM1 53 nucleoside naive 53 #F FDG PET 53 ORAL Sync 53 de novo kidney transplant 53 ARIXTRA 53 Cardiac Imaging 53 Aquapheresis 53 www.cmdiagnostics.com 53 Philadelphia Chromosome Positive 53 OvaDx 53 Personalized Oncology 53 Advanced Pancreatic Cancer 53 Tesetaxel 53 Biological Therapy 53 Diabetic Macular Edema 53 PPO EPO 53 molecular cytogenetic 53 Advexin 53 DAVANAT 53 NASDAQ CXSP announced 53 Targretin 53 TEC #OL 53 Daxor 53 fludarabine cyclophosphamide 53 Treatment Reduces 53 Sentinel Lymph Node 53 Novel Approaches 53 Portal Hypertension 53 Breast Density 53 Hyperlipidemia 53 TACI Ig 53 Multilayer Director 53 ACZ# 53 REOLYSIN ® 53 GI motility disorders 53 Gastrointestinal Oncology 53 biotherapies 53 dirucotide 53 palifosfamide 53 Phase 1b 53 oblimersen 53 Reduces Mortality 53 chronic myocardial ischemia 53 Balance Sheet Restructuring 53 Medidur TM FA 53 Solid Tumors 53 Medifacts 53 hepatocellular cancer 53 Controlled Study 53 Hexvix 53 Brain Aneurysms 53 Localized Prostate Cancer 53 Rheumatologists 53 Ischemic Stroke 53 Epiphany Biosciences 53 Dose escalation 53 Exemestane 53 Viralytics 53 Ercole Biotech 53 Numoda 53 TG MV 53 J Antimicrob Chemother 53 RESTORE CLI 53 refractory multiple myeloma 53 hepatitis C HCV 53 cutaneous T cell 53 pharmacodynamic profiles 53 double blinded placebo 53 transcranial Doppler ultrasound 53 Menopausal hormone therapy 53 Multiple Myeloma MM 53 adverse cytogenetics 53 ACCORD Lipid 53 CONQUER OB 53 Zactima 53 Hematology Molecular Pathology 53 Acute myeloid leukemia AML 53 inherited metabolic disorders 53 Treanda 53 Revlimid 53 ALSYMPCA 53 Randomized Controlled 53 Antibody Therapeutics 53 sapacitabine 53 TASQ 53 Sorafenib HCC Assessment 53 AZD# TC 53 PROCRIT ® 53 amrubicin 53 NSABP 53 cabozantinib 52 Critical Limb Ischemia CLI 52 refractory acute promyelocytic 52 CLL SLL 52 Acute Myeloid Leukemia 52 XIENCE V PROMUS Stent 52 Sentinel Lymph Node Biopsy 52 atacicept 52 BiTE antibody MT# 52 ASA# 52 eEnrollment 52 Gendux AB 52 metastatic RCC 52 unfavorable cytogenetics 52 severe oral mucositis 52 Catheter Associated 52 prospective multicenter 52 pralatrexate 52 Onyx Pharma 52 proteomic biomarkers 52 ROCKET AF 52 Inflammatory Disease 52 Florbetapir 52 Upcoming Milestones 52 mCRC 52 www.imedicor.com 52 Coronary Revascularization 52 Exploratory Clinical 52 NASDAQ ABII 52 vWD 52 Severe Asthma 52 randomized multicenter trial 52 placebo controlled clinical 52 Radiation Induced 52 Celera CRA 52 Apixaban 52 pan HDAC inhibitor 52 Telcyta 52 ON #.Na 52 Prospective Randomized Double 52 EURONEXT SAN 52 LPBP Inc. 52 PRECISE 52 trastuzumab emtansine T DM1 52 Prestara 52 Bronchiectasis 52 tolerability profiles 52 DAPT Study 52 tafamidis 52 Progenitor Cells